Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?

Author： Liberini P.   Valerio A.   Memo M.   Spano P.  

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.17, Iss.4, 1996-04, pp. : 155-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cholinesterase Inhibitors for Alzheimer's Disease

By Grutzendler J.   Morris J.C.  

Drugs, Vol. 61, Iss. 1, 2001-01 ,pp. : 41-52

Adis International

Access to resources Recommend Favorite

Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer's Disease

By Imbimbo B.P.  

CNS Drugs, Vol. 15, Iss. 5, 2001-01 ,pp. : 375-390

Adis International

Access to resources Recommend Favorite

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimer’s Disease

By Jönsson L.  

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1025-1037

Adis International

Access to resources Recommend Favorite

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease in the Elderly

By vandenBerg C.M.   Kazmi Y.   Jann M.W.  

Drugs & Aging, Vol. 16, Iss. 2, 2000-02 ,pp. : 123-138

Adis International

Access to resources Recommend Favorite

Cholinesterase Inhibitors in Alzheimer's Disease: Are they Worth the Cost?

By Whitehouse P.J.  

CNS Drugs, Vol. 11, Iss. 3, 1999-03 ,pp. : 167-173

Adis International

Access to resources Recommend Favorite